NGAL Biomarker
The NGAL biomarker provides early assessment of acute kidney injury.
An Early Warning Signal
The NGAL biomarker rises rapidly in response to kidney injury, preceding changes in creatinine by as much as 2 to 3 days.i
The NGAL biomarker has been shown to offer early clinical decision support to guide patient managementii,iii. By identifying patients at risk of AKI early, clinicians can take more appropriate action to manage fluid levels, avoid nephrotoxic agents, and potentially prevent permanent kidney damage.i
“Damage biomarkers like NGAL are an early warning signal to trigger interventions such as the KDIGO bundle.”
– DR. PRASAD DEVARAJAN, co-discoverer NGAL BIOMARKER
An Ideal Damage Biomarker
FAST
NGAL responds just 2 hours after kidney injuryiv and 2-3 days before serum creatinine rises.i
ADDITIVE
NGAL+ identifies subclinical AKI when serum creatinine alone failed to identify 43% of AKI.v
PROGNOSTIC
Identifies patients at risk of developing moderate to severe AKI.vi
RESULTS
Improved management of AKI can reduce LOS, minimize unnecessary interventions, and inform treatment choices.vii
CLINICALLY RELEVANT
The NGAL biomarker has been studied in over 16,500 patients in numerous settings including post-cardiac surgery, in critical illness, and post kidney transplantation. In each setting, “NGAL significantly improved the prediction of AKI risk over the clinical model alone.” viii
Dr. Prasad Devarajan, MD FAAP FASN discusses the NGAL biomarker, and its ability to predict AKI at an earlier stage resulting in a shift in the testing paradigm.ix
Value of an NGAL Result
Used in conjunction with clinical evaluation, NGAL provides additional data to clarify a patient’s AKI risk.
Similar to troponin for myocardial infarction, NGAL offers clinicians insight into AKI. Know days earlier which patients you need to worry about.
NGAL: The #1 Kidney Biomarker in Research
- Over 2,500 publications on PubMed in both human and animal studies.
- A CDER-qualified kidney tubular injury urinary biomarker for use in Phase 1 trials.
- FDA and EMA support the use of NGAL as a safety biomarker for early identification of renal toxicity.
BioPorto’s NGAL ELISA kits are available in six species – the bridge from pre-clinical research to clinical trials.
Join us in changing the kidney care paradigm
Stay up to date with the latest resources for kidney care, and news about BioPorto.